Equities

ValiRx PLC

VAL:LSE

ValiRx PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.00
  • Today's Change0.00 / 0.00%
  • Shares traded88.03k
  • 1 Year change-59.18%
  • Beta0.9910
Data delayed at least 20 minutes, as of Jul 04 2024 15:19 BST.
More ▼

Profile data is unavailable for this security.

About the company

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

  • Revenue in GBP (TTM)9.60k
  • Net income in GBP-2.04m
  • Incorporated2000
  • Employees8.00
  • Location
    ValiRx PLCEliot Park Innovation Centre4 Barling WayNUNEATON CV10 7RHUnited KingdomGBR
  • Phone+44 24 7679 6496Fax+44 20 3008 4415
  • Websitehttps://www.valirx.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
Fusion Antibodies PLC1.58m-2.84m2.86m50.002.86m50.00
IXICO PLC6.00m-1.87m3.45m89.003.45m89.00
TheraCryf PLC396.00k-3.14m3.63m9.003.63m9.00
ValiRx Plc9.60k-2.04m3.97m8.003.97m8.00
Cizzle Biotechnology Holdings PLC0.00-1.72m7.14m67.007.14m67.00
Destiny Pharma PLC0.00-5.66m8.14m19.008.14m19.00
Genflow Biosciences PLC0.00-1.63m8.39m5.008.39m5.00
ImmuPharma PLC0.00-2.92m8.68m5.008.68m5.00
Synairgen plc0.00-8.41m9.41m36.009.41m36.00
Bivictrix Therapeutics PLC0.00-2.55m10.32m12.0010.32m12.00
Shield Therapeutics PLC13.09m-33.29m13.69m73.0013.69m73.00
Data as of Jul 04 2024. Currency figures normalised to ValiRx PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.